PBAC's latest decision on Dutasteride with tamsulosin hydrochloride: Recommended with restriction (2010). Considered for Treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) where treatment has been initiated by a urologist.
PBAC outcome
Recommended with restriction
Authority Required (STREAMLINED)
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2010
Submissions
1
2010 → 2010
Eligible population
Treatment of lower urinary tract symptoms due to benign prostatic hyperplasia where treatment has been initiated by a urologist.
Therapy area
Urology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
QoL, IPSS, Qmax
Key trials
ARI4005, CombAT (Chapple et al), ARI109882, Chapple 2005, Mohanty 2003, Steven 1993
Comparator
co-administered dutasteride and prazosin
Economic model
Cost-minimisation
Eligible patients/year
100,000
ICER note
Cost minimisation analysis conducted; no ICER calculated by design